Tc 99m NC 100586

Drug Profile

Tc 99m NC 100586

Alternative Names: 99m-Tc-NC100586

Latest Information Update: 08 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare; Targeted Diagnostics and Therapeutics
  • Developer GE Healthcare; Targeted Diagnostics and Therapeutics; Thomas Jefferson University
  • Class Heavy metals; Radiopharmaceuticals
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Sep 2006 Discontinued - Preclinical for Solid tumour diagnosis in USA (IV)
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 14 Nov 2002 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top